Overview
EGFR Inhibitors – RJS012 and RJS013
This series contains RJS Biologics’s therapeutic cancer product candidates generated from our innovative drug delivery platform designed to produce therapeutics that selectively target lung cancer cells.
Current epidermal growth factor inhibitor (EGFRI) therapies may be less toxic than adverse reactions to many other forms of chemotherapy, however the skin reactions caused lead one in ten patients to interrupt or even discontinue therapy. In vitro examination of this class of compounds leads RJSbio to believe we have more focused drugs with a greater preference for cancer cells over normal cells. Less rash, more therapy, we’ll see… Currently we are evaluating these candidates in preclinical models of cancer. Please check back for more information and our progress.
Anthracyclines – RJS010
This series contains RJS Biologics’s therapeutic cancer product candidates generated from our innovative drug delivery platform designed to produce therapeutics that selectively target leukemia and lymphoma cells.
Current Doxorubicin based therapies may be of great utility because they may lead to complete remission. However, the adverse reactions of Doxorubicin may be catastrophic to the patient. Up to 5% of patients may have evidence of congestive heart failure or a significant decline in heart function as a result of current Doxorubicin treatment regimes. 65% of children treated for childhood malignancy with Doxorubicin can have lasting heart abnormalities. In vitro examination of this class of compounds leads RJSbio to believe we have more focused drugs with a greater preference for cancer cells over normal cells. Less heart damage, more cancer cell damage, we’ll see… Currently we are evaluating these candidates in cell based models of cancer. Please check back for more information and our progress.
Artemisinins – RJS05X
This series contains RJS Biologics’s therapeutic cancer product candidates generated from our innovative drug delivery platform designed to produce therapeutics that selectively target leukemia and lymphoma cells.
Forms of Artemisinin have been used by Chinese herbalists thousands of years in the treatment of many illnesses, such as skin diseases and malaria. This is quite a track record of safety. However, by itself Artemisinin is of little utility in cancer treatments. With focused delivery Artemisinin becomes a potent weapon against cancer. Artemisinin reacts with intracellular iron to generate toxic radical species. Some cancer cells, notably leukemia and lymphoma cells, intake large quantities of the essential nutrient iron through up-regulation of transferrin receptor. Intracellular iron and Artemisinin may be a deadly combination to a cancer cell. Currently we are evaluating these candidates in preclinical models of cancer. Please check back for more information and our progress.
Diagnostic Payloads
Our tetheriing technology allows RJSBio to create companion imaging agents intended for diagnostic use with each of our cancer drug candidates. To create our companion imaging agents, we simply replace the drug payload an imaging agent that can be viewed within an animal model. We are just designing these reagents, but the goal is to evaluate real-time images of our drugs fighting cancer. Please check back for more information and progress.